CRISPR Enters the Nursery: The Pediatric Cure That Rewrites Healthcare Economics

The FDA's expansion of Casgevy to children as young as two marks the transition of gene editing from rare adult therapy to scalable pediatric cure, fundamentally altering disease trajectories and healthcare economics. This shift from chronic management to early-life eradication promises lifetime cost savings of 60-70% while exposing critical gaps in global access and regulatory infrastructure.